Full Class II De Novo FDA Submission seeking clearance of the Parsortix system for metastatic breast cancer has successfully completed FDA administrative review ANGLE believes that the earliest ...

Operating costs for the year reduced by 27% to £16.9 million (2023: £23.3 million) Loss for the year reduced by 29% to £14.2 million, or 4.82 pence per share (FY23: loss £20.1 million, or 7.73 pence ...

ANGLE is a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology using a simple blood sample. ANGLE's ...

ANGLE is a world-leading liquid biopsy company with sample-to-answer solutions. ANGLE's proven patent-protected platforms include a circulating tumor cell (CTC) harvesting technology and a downstream ...

GUILDFORD, UK / ACCESSWIRE / November 15, 2021 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, announces that, under the Remuneration Policy approved by the shareholders at ...

GUILDFORD, SURREY / ACCESS Newswire / June 17, 2025 / ANGLE plc (AIM:AGL) (OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in ...

BREAKTHROUGH RESEARCH DEMONSTRATES A PARSORTIX TEST COULD AVOID UNNECESSARY PROSTATE BIOPSIES Barts Cancer Institute demonstrates capability of Parsortix system to detect clinically significant ...

GUILDFORD, SURREY / ACCESSWIRE / January 5, 2023 / ANGLE plc ("the Company") (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that Juliet Thompson has been ...

GUILDFORD, SURREY / ACCESSWIRE / January 22, 2020 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company, is delighted to announce that a successful face-to-face meeting with the ...

GUILDFORD, SURREY / ACCESS Newswire / September 9, 2025 / ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in ...